<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01978184</url>
  </required_header>
  <id_info>
    <org_study_id>UPCI# 13-074</org_study_id>
    <nct_id>NCT01978184</nct_id>
  </id_info>
  <brief_title>Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine</brief_title>
  <official_title>Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nathan Bahary, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized phase II trial that will examine the ability of the hydroxychloroquine
      to improve the clinical activity of a pre-operative regimen of gemcitabine and nab-paclitaxel
      in subjects with potentially resectable adenocarcinoma of the pancreas. Eligible subjects
      will receive 2 cycles of gemcitabine and nab-paclitaxel (day 1, 8, 15) with or without
      hydrocychloroquine followed by surgical resection. Primary endpoint will be histologic
      response as graded by Evans criteria. Secondary endpoints will be CA19-9 response and PET
      response. Pre and post treatment tissue biopsies will be obtained to assess for levels of
      autophagy in tumor, liver and peripheral blood.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">February 28, 2018</completion_date>
  <primary_completion_date type="Actual">February 6, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evans Grade Histopathologic Response</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>The number of patients who exhibited an Evans grade Histologic response (I, IIA, IIB, or III) to pre-operative gemcitabine / nab-paclitaxel. Histological response validated scoring system by Evans is as follows: Grade I: 1-9% tumor destruction, Grade II: 10 - 90%, Grade III: &gt;90% tumor destruction (Grade IIA = 10-50% of tumor cells destroyed; Grade IIB = 50-90% of tumor cells destroyed), Grade IV: Absence of viable tumor cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Age at Diagnosis</measure>
    <time_frame>Baseline - At the time of diagnosis, prior to treatment</time_frame>
    <description>The mean age of patients at the time of diagnosis of disease (as a variable in the proportional odds logistic regression, secondary analysis of Evans Grade).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CT Tumor Size</measure>
    <time_frame>Baseline - At the time of diagnosis, prior to treatment</time_frame>
    <description>Tumor size as measured via computerized tomography (CT) scan (as a variable in the proportional odds logistic regression, secondary analysis of Evans Grade).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cancer Diagnosis Stage</measure>
    <time_frame>Baseline - At the time of diagnosis, prior to treatment</time_frame>
    <description>The number of participants in cancer diagnosis stage groups. Stage 0: cancer hasn't spread to nearby tissues/located in the same of origin.Stage I: cancers hasn't grown deeply into nearby tissues or spread to lymph nodes or other parts of the body. Stage II and III: cancers have grown more deeply into nearby tissues (may have metastasized to lymph nodes but not other parts of the body). Stage IV: most advanced stage (metastatic cancer) ; cancer has spread to other parts of the body. Stages subdivided further into the categories &quot;A&quot; (less agressive disease) and &quot;B&quot; (more advanced cancer). Example: stage IIA is less aggressive than stage IIB, but stage IIIA is more aggressive than stage IIB. (Stage variable used in the proportional odds logistic regression, secondary analysis of Evans Grade).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Type of Surgical Procedure (Operation)</measure>
    <time_frame>At the time of surgery (≥2 weeks and ≤6 weeks post chemotherapy)</time_frame>
    <description>The number of participants in having each type of surgical resection procedure: Celiac Axis Resection With Distal Pancreatectomy (DPCAR) (Modified Appleby), Distal Pancreatectomy, Total Pancreatectomy, or Whipple. (Operation variable used in the proportional odds logistic regression, secondary analysis of Evans Grade).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Robotic Resection Surgery</measure>
    <time_frame>At the time of surgery (≥2 weeks and ≤6 weeks post chemotherapy)</time_frame>
    <description>The number of participants who had robotic resection surgery. (Robotic surgery variable used in the proportional odds logistic regression, secondary analysis of Evans Grade).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Age-Adjusted Charlson Comorbidity Index</measure>
    <time_frame>Prior to treatment</time_frame>
    <description>The Charlson Comorbidity Index is a method of categorizing comorbidities of patients based on the International Classification of Diseases (ICD) diagnosis codes found in administrative data, such as hospital abstracts data. Each comorbidity category has an associated weight (from 1 to 6), based on the adjusted risk of mortality or resource use, and the sum of all the weights results in a single comorbidity score for a patient. A score of zero indicates that no comorbidities were found. The higher the score, the more likely the predicted outcome will result in mortality or higher resource use. Up to 12 comorbidities with various weightings can result in a maximum score of 24. The minimum score is zero.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Carbohydrate Antigen 19-9 (CA19-9) Response</measure>
    <time_frame>Prior to treatment (average 73.3 +/- 9.9 days prior to surgery)</time_frame>
    <description>Levels of Carbohydrate antigen 19-9 (CA19-9) response to pre-operative gemcitabine/ nab-paclitaxel measured in the serum (original scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carbohydrate Antigen 19-9 (CA19-9) Response</measure>
    <time_frame>After treatment (50-67 days post treatment/surgery)</time_frame>
    <description>Levels of Carbohydrate antigen 19-9 (CA19-9) response to pre-operative gemcitabine/ nab-paclitaxel measured in the serum (original scale).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Lymph Node Involvement</measure>
    <time_frame>At the time of surgery (≥2 weeks and ≤6 weeks post chemotherapy)</time_frame>
    <description>The proportion of participants with positive (disease) lymph nodes involvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of R0 Resection</measure>
    <time_frame>At the time of surgery (≥2 weeks and ≤6 weeks post chemotherapy)</time_frame>
    <description>The proportion of participants having resection for cure or complete remission, in which the surgical margins are negative for tumor cells. R0 resection indicates a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>gemcitabine and abraxane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine and Abraxane will be administered on an outpatient basis on Days 3, 10, 17, 31, 38, and 45 as an intravenous infusion. The dose on Day 3 will be 1000 mg/m of gemcitabine followed by a 125 mg/m2 of abraxane and the infusion will take 1 hour. The second dose and infusion time may be decreased. Prior to each gemcitabine infusion, subjects will be pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gemcitabine, abraxane and hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine and Abraxane will be administered on an outpatient basis on Days 3, 10, 17, 31, 38, and 45 as an intravenous infusion. The dose on Day 3 will be 1000 mg/m of gemcitabine followed by a 125 mg/m2 of abraxane and the infusion will take 1 hour. The second dose and infusion time may be decreased. Prior to each gemcitabine infusion, subjects will be pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
Hydroxychloroquine is an oral drug (capsule) that subjects will take once or twice a day at home. The dose of hydroxychlorquien will be 1200mg. This is an experimental drug. Subjects will take their first dose of hydroxychloroquine on Day 1 (48 hours before the first infusion of gemcitabine/abraxane), and will continue to take it every day until the day before surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <arm_group_label>gemcitabine and abraxane</arm_group_label>
    <arm_group_label>gemcitabine, abraxane and hydroxychloroquine</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abraxane</intervention_name>
    <arm_group_label>gemcitabine and abraxane</arm_group_label>
    <arm_group_label>gemcitabine, abraxane and hydroxychloroquine</arm_group_label>
    <other_name>nab-Paclitacel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydroxychloroquine</intervention_name>
    <arm_group_label>gemcitabine, abraxane and hydroxychloroquine</arm_group_label>
    <other_name>Plaquenil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with biopsy-proven potentially resectable or borderline adenocarcinoma of the
             pancreas as determined by National Comprehensive Cancer Network (NCCN) criteria

          -  Karnofsky performance status of 70-100%

          -  No active second malignancy except for basal cell carcinoma of the skin

          -  Patient has adequate biological parameters as demonstrated by the following blood
             counts at screening

          -  Absolute neutrophil count (ANC) ≥1.5 × 109/L;

          -  Platelet count ≥100,000/mm3 (100 × 109/L);

          -  Hemoglobin (Hgb) ≥9 g/dL.

          -  Patient has the following blood chemistry levels at Baseline

          -  aspartate aminotransferase (AST) (SGOT), Alanine transaminase (SGPT) ≤2.5 × upper
             limit of normal range (ULN)

          -  Total bilirubin ≤ULN

          -  Serum Creatinine ≤ 1.5mg/dl OR calculated creatinine clearance ≥ 50 for those patients
             with creatinine greater than 1.5

          -  Prothrombin time (PT)within normal limits (WNL). If patient is on warfarin for
             prophylactic clot presentation for indwelling catheter, Partial PT/PTT may be +/- 15 %

          -  thromboplastin time (PTT) WNL. If patient on warfarin for prophylactic clot
             presentation for indwelling catheter, PT/PTT may be +/- 15 %

          -  Age &gt;18 years.

          -  Patient must be able to swallow enteral medications with no requirement for a feeding
             tube. Patient's must not have intractable nausea or vomiting which prohibits the
             patient from oral medications

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Subjects deemed surgically unresectable or subjects unwilling to undergo surgical
             resection.

          -  Subjects who have received chemotherapy within 12 months prior to randomization.

          -  Prior use of radiotherapy or investigational agents for pancreatic cancer.

          -  Any evidence of metastasis to distant organs (liver, lung, peritoneum).

          -  Symptomatic evidence of gastric outlet obstruction

          -  Inability to adhere to study and/or follow-up procedures

          -  History of allergic reactions or hypersensitivity to the study drugs
             (hydroxychloroquine, gemcitabine, abraxane).

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for
             the duration of study participation. All females of childbearing potential must have a
             blood test or urine study within two weeks prior to randomization to rule out
             pregnancy.

          -  Patients with porphyria are ineligible.

          -  Patients with psoriasis are ineligible unless the disease is well controlled and they
             are under the care of a specialist who agrees to monitor the patient for
             exacerbations.

          -  Patients requiring the use of enzyme-inducing anti-epileptic medication that includes:
             phenytoin, carbamazepine, phenobarbital, primidone or oxcarbazepine are excluded.

          -  Patients with previously documented macular degeneration or diabetic retinopathy are
             excluded.

          -  Baseline electrocardiogram (EKG) with corrected QT interval (QTc) &gt;470 msec (including
             subjects on medication). Subjects with ventricular pacemaker for whom QT interval is
             not measurable will be eligible on a case-by-case basis.

          -  Patient with a history of interstitial lung disease, history of slowly progressive
             dyspnea, sarcoidosis, silicosis, idiopathic pulmonary fibrosis or pulmonary
             hypersensitivity pneumonitis

          -  Patient with known active infection with HIV, Hepatitis B or Hepatitis C

          -  Patients requiring use of warfarin for therapeutic purposes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert Zeh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh CancerCenters</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>October 30, 2013</study_first_submitted>
  <study_first_submitted_qc>November 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2013</study_first_posted>
  <results_first_submitted>March 3, 2019</results_first_submitted>
  <results_first_submitted_qc>March 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 27, 2019</results_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Nathan Bahary, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Pancreatic Cancer, resectable adenocarcinoma of the pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT01978184/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gemcitabine + Abraxane</title>
          <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.</description>
        </group>
        <group group_id="P2">
          <title>Gemcitabine + Abraxane and Hydroxychloroquine</title>
          <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
Hydroxychloroquine oral capsules taken once or twice a daily at a dose of 1200mg. The first dose of hydroxychloroquine taken on Day 1 (48 hours before the first infusion of gemcitabine/abraxane), and continued daily until one day before surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than PDA</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew- toxicities or physical decline</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gemcitabine + Abraxane</title>
          <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.</description>
        </group>
        <group group_id="B2">
          <title>Gemcitabine + Abraxane and Hydroxychloroquine</title>
          <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
Hydroxychloroquine oral capsules taken once or twice a daily at a dose of 1200mg. The first dose of hydroxychloroquine taken on Day 1 (48 hours before the first infusion of gemcitabine/abraxane), and continued daily until one day before surgery.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="71"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.6" spread="11.8"/>
                    <measurement group_id="B2" value="66.1" spread="8.4"/>
                    <measurement group_id="B3" value="65" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evans Grade Histopathologic Response</title>
        <description>The number of patients who exhibited an Evans grade Histologic response (I, IIA, IIB, or III) to pre-operative gemcitabine / nab-paclitaxel. Histological response validated scoring system by Evans is as follows: Grade I: 1-9% tumor destruction, Grade II: 10 - 90%, Grade III: &gt;90% tumor destruction (Grade IIA = 10-50% of tumor cells destroyed; Grade IIB = 50-90% of tumor cells destroyed), Grade IV: Absence of viable tumor cells.</description>
        <time_frame>Up to 4 years</time_frame>
        <population>Patients who went to surgery and were evaluable for Evans Grade Histopathologic Response.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine + Abraxane</title>
            <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.</description>
          </group>
          <group group_id="O2">
            <title>Gemcitabine + Abraxane and Hydroxychloroquine</title>
            <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
Hydroxychloroquine oral capsules taken once or twice a daily at a dose of 1200mg. The first dose of hydroxychloroquine taken on Day 1 (48 hours before the first infusion of gemcitabine/abraxane), and continued daily until one day before surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Evans Grade Histopathologic Response</title>
          <description>The number of patients who exhibited an Evans grade Histologic response (I, IIA, IIB, or III) to pre-operative gemcitabine / nab-paclitaxel. Histological response validated scoring system by Evans is as follows: Grade I: 1-9% tumor destruction, Grade II: 10 - 90%, Grade III: &gt;90% tumor destruction (Grade IIA = 10-50% of tumor cells destroyed; Grade IIB = 50-90% of tumor cells destroyed), Grade IV: Absence of viable tumor cells.</description>
          <population>Patients who went to surgery and were evaluable for Evans Grade Histopathologic Response.</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Evans grade - I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evans grade - IIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evans grade - IIB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evans grade - III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Age at Diagnosis</title>
        <description>The mean age of patients at the time of diagnosis of disease (as a variable in the proportional odds logistic regression, secondary analysis of Evans Grade).</description>
        <time_frame>Baseline - At the time of diagnosis, prior to treatment</time_frame>
        <population>Patients who went to surgery and were evaluable for Evans Grade Histopathologic Response.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine + Abraxane</title>
            <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.</description>
          </group>
          <group group_id="O2">
            <title>Gemcitabine + Abraxane and Hydroxychloroquine</title>
            <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
Hydroxychloroquine oral capsules taken once or twice a daily at a dose of 1200mg. The first dose of hydroxychloroquine taken on Day 1 (48 hours before the first infusion of gemcitabine/abraxane), and continued daily until one day before surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Age at Diagnosis</title>
          <description>The mean age of patients at the time of diagnosis of disease (as a variable in the proportional odds logistic regression, secondary analysis of Evans Grade).</description>
          <population>Patients who went to surgery and were evaluable for Evans Grade Histopathologic Response.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6" spread="11.8"/>
                    <measurement group_id="O2" value="66.1" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CT Tumor Size</title>
        <description>Tumor size as measured via computerized tomography (CT) scan (as a variable in the proportional odds logistic regression, secondary analysis of Evans Grade).</description>
        <time_frame>Baseline - At the time of diagnosis, prior to treatment</time_frame>
        <population>Patients who went to surgery and were evaluable for Evans Grade Histopathologic Response.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine + Abraxane</title>
            <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.</description>
          </group>
          <group group_id="O2">
            <title>Gemcitabine + Abraxane and Hydroxychloroquine</title>
            <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
Hydroxychloroquine oral capsules taken once or twice a daily at a dose of 1200mg. The first dose of hydroxychloroquine taken on Day 1 (48 hours before the first infusion of gemcitabine/abraxane), and continued daily until one day before surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>CT Tumor Size</title>
          <description>Tumor size as measured via computerized tomography (CT) scan (as a variable in the proportional odds logistic regression, secondary analysis of Evans Grade).</description>
          <population>Patients who went to surgery and were evaluable for Evans Grade Histopathologic Response.</population>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.562069" spread="1.105962"/>
                    <measurement group_id="O2" value="2.543056" spread="1.139370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cancer Diagnosis Stage</title>
        <description>The number of participants in cancer diagnosis stage groups. Stage 0: cancer hasn't spread to nearby tissues/located in the same of origin.Stage I: cancers hasn't grown deeply into nearby tissues or spread to lymph nodes or other parts of the body. Stage II and III: cancers have grown more deeply into nearby tissues (may have metastasized to lymph nodes but not other parts of the body). Stage IV: most advanced stage (metastatic cancer) ; cancer has spread to other parts of the body. Stages subdivided further into the categories &quot;A&quot; (less agressive disease) and &quot;B&quot; (more advanced cancer). Example: stage IIA is less aggressive than stage IIB, but stage IIIA is more aggressive than stage IIB. (Stage variable used in the proportional odds logistic regression, secondary analysis of Evans Grade).</description>
        <time_frame>Baseline - At the time of diagnosis, prior to treatment</time_frame>
        <population>Patients who went to surgery and were evaluable for Evans Grade Histopathologic Response.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine + Abraxane</title>
            <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.</description>
          </group>
          <group group_id="O2">
            <title>Gemcitabine + Abraxane and Hydroxychloroquine</title>
            <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
Hydroxychloroquine oral capsules taken once or twice a daily at a dose of 1200mg. The first dose of hydroxychloroquine taken on Day 1 (48 hours before the first infusion of gemcitabine/abraxane), and continued daily until one day before surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Cancer Diagnosis Stage</title>
          <description>The number of participants in cancer diagnosis stage groups. Stage 0: cancer hasn't spread to nearby tissues/located in the same of origin.Stage I: cancers hasn't grown deeply into nearby tissues or spread to lymph nodes or other parts of the body. Stage II and III: cancers have grown more deeply into nearby tissues (may have metastasized to lymph nodes but not other parts of the body). Stage IV: most advanced stage (metastatic cancer) ; cancer has spread to other parts of the body. Stages subdivided further into the categories &quot;A&quot; (less agressive disease) and &quot;B&quot; (more advanced cancer). Example: stage IIA is less aggressive than stage IIB, but stage IIIA is more aggressive than stage IIB. (Stage variable used in the proportional odds logistic regression, secondary analysis of Evans Grade).</description>
          <population>Patients who went to surgery and were evaluable for Evans Grade Histopathologic Response.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IIB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Type of Surgical Procedure (Operation)</title>
        <description>The number of participants in having each type of surgical resection procedure: Celiac Axis Resection With Distal Pancreatectomy (DPCAR) (Modified Appleby), Distal Pancreatectomy, Total Pancreatectomy, or Whipple. (Operation variable used in the proportional odds logistic regression, secondary analysis of Evans Grade).</description>
        <time_frame>At the time of surgery (≥2 weeks and ≤6 weeks post chemotherapy)</time_frame>
        <population>Patients who went to surgery and were evaluable for Evans Grade Histopathologic Response.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine + Abraxane</title>
            <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.</description>
          </group>
          <group group_id="O2">
            <title>Gemcitabine + Abraxane and Hydroxychloroquine</title>
            <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
Hydroxychloroquine oral capsules taken once or twice a daily at a dose of 1200mg. The first dose of hydroxychloroquine taken on Day 1 (48 hours before the first infusion of gemcitabine/abraxane), and continued daily until one day before surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Type of Surgical Procedure (Operation)</title>
          <description>The number of participants in having each type of surgical resection procedure: Celiac Axis Resection With Distal Pancreatectomy (DPCAR) (Modified Appleby), Distal Pancreatectomy, Total Pancreatectomy, or Whipple. (Operation variable used in the proportional odds logistic regression, secondary analysis of Evans Grade).</description>
          <population>Patients who went to surgery and were evaluable for Evans Grade Histopathologic Response.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DPCAR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal Pancreatectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Pancreatectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Whipple</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Robotic Resection Surgery</title>
        <description>The number of participants who had robotic resection surgery. (Robotic surgery variable used in the proportional odds logistic regression, secondary analysis of Evans Grade).</description>
        <time_frame>At the time of surgery (≥2 weeks and ≤6 weeks post chemotherapy)</time_frame>
        <population>Patients who went to surgery and were evaluable for Evans Grade Histopathologic Response.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine + Abraxane</title>
            <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.</description>
          </group>
          <group group_id="O2">
            <title>Gemcitabine + Abraxane and Hydroxychloroquine</title>
            <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
Hydroxychloroquine oral capsules taken once or twice a daily at a dose of 1200mg. The first dose of hydroxychloroquine taken on Day 1 (48 hours before the first infusion of gemcitabine/abraxane), and continued daily until one day before surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Robotic Resection Surgery</title>
          <description>The number of participants who had robotic resection surgery. (Robotic surgery variable used in the proportional odds logistic regression, secondary analysis of Evans Grade).</description>
          <population>Patients who went to surgery and were evaluable for Evans Grade Histopathologic Response.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes - robotic surgical resection procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No - not robotic surgical resection procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Age-Adjusted Charlson Comorbidity Index</title>
        <description>The Charlson Comorbidity Index is a method of categorizing comorbidities of patients based on the International Classification of Diseases (ICD) diagnosis codes found in administrative data, such as hospital abstracts data. Each comorbidity category has an associated weight (from 1 to 6), based on the adjusted risk of mortality or resource use, and the sum of all the weights results in a single comorbidity score for a patient. A score of zero indicates that no comorbidities were found. The higher the score, the more likely the predicted outcome will result in mortality or higher resource use. Up to 12 comorbidities with various weightings can result in a maximum score of 24. The minimum score is zero.</description>
        <time_frame>Prior to treatment</time_frame>
        <population>Patients who went to surgery and were evaluable for Evans Grade Histopathologic Response.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine + Abraxane</title>
            <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.</description>
          </group>
          <group group_id="O2">
            <title>Gemcitabine + Abraxane and Hydroxychloroquine</title>
            <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
Hydroxychloroquine oral capsules taken once or twice a daily at a dose of 1200mg. The first dose of hydroxychloroquine taken on Day 1 (48 hours before the first infusion of gemcitabine/abraxane), and continued daily until one day before surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Age-Adjusted Charlson Comorbidity Index</title>
          <description>The Charlson Comorbidity Index is a method of categorizing comorbidities of patients based on the International Classification of Diseases (ICD) diagnosis codes found in administrative data, such as hospital abstracts data. Each comorbidity category has an associated weight (from 1 to 6), based on the adjusted risk of mortality or resource use, and the sum of all the weights results in a single comorbidity score for a patient. A score of zero indicates that no comorbidities were found. The higher the score, the more likely the predicted outcome will result in mortality or higher resource use. Up to 12 comorbidities with various weightings can result in a maximum score of 24. The minimum score is zero.</description>
          <population>Patients who went to surgery and were evaluable for Evans Grade Histopathologic Response.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Age-Adjusted CCI=2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age-Adjusted CCI=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age-Adjusted CCI=4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age-Adjusted CCI=5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age-Adjusted CCI=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age-Adjusted CCI=7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age-Adjusted CCI=8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Carbohydrate Antigen 19-9 (CA19-9) Response</title>
        <description>Levels of Carbohydrate antigen 19-9 (CA19-9) response to pre-operative gemcitabine/ nab-paclitaxel measured in the serum (original scale)</description>
        <time_frame>Prior to treatment (average 73.3 +/- 9.9 days prior to surgery)</time_frame>
        <population>Participants that were assigned to treatment and did not withdraw consent prior to being given drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine + Abraxane</title>
            <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.</description>
          </group>
          <group group_id="O2">
            <title>Gemcitabine + Abraxane and Hydroxychloroquine</title>
            <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
Hydroxychloroquine oral capsules taken once or twice a daily at a dose of 1200mg. The first dose of hydroxychloroquine taken on Day 1 (48 hours before the first infusion of gemcitabine/abraxane), and continued daily until one day before surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Carbohydrate Antigen 19-9 (CA19-9) Response</title>
          <description>Levels of Carbohydrate antigen 19-9 (CA19-9) response to pre-operative gemcitabine/ nab-paclitaxel measured in the serum (original scale)</description>
          <population>Participants that were assigned to treatment and did not withdraw consent prior to being given drug.</population>
          <units>units per milliliter (U/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="351.820" spread="839.925"/>
                    <measurement group_id="O2" value="1534.633" spread="3558.1212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Carbohydrate Antigen 19-9 (CA19-9) Response</title>
        <description>Levels of Carbohydrate antigen 19-9 (CA19-9) response to pre-operative gemcitabine/ nab-paclitaxel measured in the serum (original scale).</description>
        <time_frame>After treatment (50-67 days post treatment/surgery)</time_frame>
        <population>Participants that were assigned to treatment and did not withdraw consent prior to being given drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine + Abraxane</title>
            <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.</description>
          </group>
          <group group_id="O2">
            <title>Gemcitabine + Abraxane and Hydroxychloroquine</title>
            <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
Hydroxychloroquine oral capsules taken once or twice a daily at a dose of 1200mg. The first dose of hydroxychloroquine taken on Day 1 (48 hours before the first infusion of gemcitabine/abraxane), and continued daily until one day before surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Carbohydrate Antigen 19-9 (CA19-9) Response</title>
          <description>Levels of Carbohydrate antigen 19-9 (CA19-9) response to pre-operative gemcitabine/ nab-paclitaxel measured in the serum (original scale).</description>
          <population>Participants that were assigned to treatment and did not withdraw consent prior to being given drug.</population>
          <units>units per milliliter (U/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="319.079" spread="1338.259"/>
                    <measurement group_id="O2" value="1696.710" spread="9850.273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive Lymph Node Involvement</title>
        <description>The proportion of participants with positive (disease) lymph nodes involvement.</description>
        <time_frame>At the time of surgery (≥2 weeks and ≤6 weeks post chemotherapy)</time_frame>
        <population>Participants that were assigned to treatment and did not withdraw consent prior to being given drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine + Abraxane</title>
            <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.</description>
          </group>
          <group group_id="O2">
            <title>Gemcitabine + Abraxane and Hydroxychloroquine</title>
            <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
Hydroxychloroquine oral capsules taken once or twice a daily at a dose of 1200mg. The first dose of hydroxychloroquine taken on Day 1 (48 hours before the first infusion of gemcitabine/abraxane), and continued daily until one day before surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Lymph Node Involvement</title>
          <description>The proportion of participants with positive (disease) lymph nodes involvement.</description>
          <population>Participants that were assigned to treatment and did not withdraw consent prior to being given drug.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.614" upper_limit="0.923"/>
                    <measurement group_id="O2" value="0.561" lower_limit="0.397" upper_limit="0.715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of R0 Resection</title>
        <description>The proportion of participants having resection for cure or complete remission, in which the surgical margins are negative for tumor cells. R0 resection indicates a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed.</description>
        <time_frame>At the time of surgery (≥2 weeks and ≤6 weeks post chemotherapy)</time_frame>
        <population>Participants that were assigned to treatment and did not withdraw consent prior to being given drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine + Abraxane</title>
            <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.</description>
          </group>
          <group group_id="O2">
            <title>Gemcitabine + Abraxane and Hydroxychloroquine</title>
            <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
Hydroxychloroquine oral capsules taken once or twice a daily at a dose of 1200mg. The first dose of hydroxychloroquine taken on Day 1 (48 hours before the first infusion of gemcitabine/abraxane), and continued daily until one day before surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of R0 Resection</title>
          <description>The proportion of participants having resection for cure or complete remission, in which the surgical margins are negative for tumor cells. R0 resection indicates a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed.</description>
          <population>Participants that were assigned to treatment and did not withdraw consent prior to being given drug.</population>
          <units>proportion of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.506" upper_limit="0.853"/>
                    <measurement group_id="O2" value="0.829" lower_limit="0.679" upper_limit="0.928"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 4 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gemcitabine + Abraxane</title>
          <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.</description>
        </group>
        <group group_id="E2">
          <title>Gemcitabine + Abraxane and Hydroxychloroquine</title>
          <description>Gemcitabine and Abraxane administered as an intravenous infusion on Study Days 3, 10, 17, 31, 38, and 45. Day 3 dosing: 1 hour infusion - 1000 mg/m^2 of gemcitabine followed by a 125 mg/m^2 of abraxane. Prior to each gemcitabine infusion, subjects were pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
Hydroxychloroquine oral capsules taken once or twice a daily at a dose of 1200mg. The first dose of hydroxychloroquine taken on Day 1 (48 hours before the first infusion of gemcitabine/abraxane), and continued daily until one day before surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="13" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="12" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="18" subjects_affected="5" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="21" subjects_affected="6" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="12" subjects_affected="4" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="30" subjects_affected="10" subjects_at_risk="43"/>
                <counts group_id="E2" events="45" subjects_affected="11" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E2" events="39" subjects_affected="10" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="21" subjects_affected="5" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="24" subjects_affected="6" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="9" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="151" subjects_affected="36" subjects_at_risk="43"/>
                <counts group_id="E2" events="333" subjects_affected="50" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E2" events="27" subjects_affected="7" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Cardiac disorders - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Paroxysmal atrial tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pulmonary valve disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Tricuspid valve disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="9" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Eye disorders - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" events="24" subjects_affected="8" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="26" subjects_affected="10" subjects_at_risk="43"/>
                <counts group_id="E2" events="42" subjects_affected="13" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="27" subjects_affected="11" subjects_at_risk="43"/>
                <counts group_id="E2" events="100" subjects_affected="25" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Esophageal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="10" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="15" subjects_affected="5" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="15" subjects_affected="4" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="24" subjects_affected="7" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Malabsorption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="41" subjects_affected="12" subjects_at_risk="43"/>
                <counts group_id="E2" events="126" subjects_affected="31" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="19" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E2" events="48" subjects_affected="16" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="13" subjects_affected="4" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="18" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E2" events="21" subjects_affected="7" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Edema trunk</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="86" subjects_affected="29" subjects_at_risk="43"/>
                <counts group_id="E2" events="141" subjects_affected="27" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="16" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E2" events="28" subjects_affected="8" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="12" subjects_affected="4" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" events="20" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" events="24" subjects_affected="7" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" events="12" subjects_affected="4" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="20" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="18" subjects_affected="5" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injury, poisoning and procedural complications - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="56" subjects_affected="18" subjects_at_risk="43"/>
                <counts group_id="E2" events="147" subjects_affected="32" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="27" subjects_affected="11" subjects_at_risk="43"/>
                <counts group_id="E2" events="105" subjects_affected="23" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="51" subjects_affected="17" subjects_at_risk="43"/>
                <counts group_id="E2" events="135" subjects_affected="36" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="27" subjects_affected="7" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>CPK increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" events="12" subjects_affected="4" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hemoglobin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="37" subjects_affected="13" subjects_at_risk="43"/>
                <counts group_id="E2" events="63" subjects_affected="13" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="123" subjects_affected="29" subjects_at_risk="43"/>
                <counts group_id="E2" events="198" subjects_affected="41" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="113" subjects_affected="30" subjects_at_risk="43"/>
                <counts group_id="E2" events="228" subjects_affected="45" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Serum amylase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E2" events="18" subjects_affected="5" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="122" subjects_affected="31" subjects_at_risk="43"/>
                <counts group_id="E2" events="237" subjects_affected="42" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" events="39" subjects_affected="12" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" events="36" subjects_affected="9" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="92" subjects_affected="25" subjects_at_risk="43"/>
                <counts group_id="E2" events="204" subjects_affected="40" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="30" subjects_affected="6" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="11" subjects_at_risk="43"/>
                <counts group_id="E2" events="81" subjects_affected="20" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="53" subjects_affected="17" subjects_at_risk="43"/>
                <counts group_id="E2" events="150" subjects_affected="28" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="24" subjects_affected="4" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders - Other, specify</sub_title>
                <counts group_id="E1" events="10" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="18" subjects_affected="5" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="57" subjects_affected="10" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="12" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="12" subjects_affected="3" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="9" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="12" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="24" subjects_affected="6" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="15" subjects_affected="5" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="18" subjects_affected="5" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="18" subjects_affected="6" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="39" subjects_affected="10" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Nail discoloration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="12" subjects_affected="4" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="33" subjects_affected="8" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="59" subjects_affected="13" subjects_at_risk="43"/>
                <counts group_id="E2" events="60" subjects_affected="14" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="33" subjects_affected="9" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Superficial thrombophlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="7" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Vascular disorders - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Barbara Stadterman</name_or_title>
      <organization>UPMC Hillman Cancer Center</organization>
      <phone>412-647-5554</phone>
      <email>stadtermanbm@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

